Sinonasal mucosal melanoma in The Netherlands between 2001 and 2021: a clinical and epidemiological overview of 320 cases
verfasst von:
W. F. Julius Scheurleer, Lise J. van de Velde, Lot A. Devriese, Mischa de Ridder, Marieke W. J. Louwman, Gerben E. Breimer, Remco de Bree, Boukje A. C. van Dijk, Johannes A. Rijken
Sinonasal mucosal melanoma (SNMM) is a rare malignancy, characterised by high (local) recurrence rates and poor survival. Comprehensive understanding of tumour etiology is currently lacking, which complicates adequate tumour treatment. Besides examining trends in incidence, this study aims to assess the association between clinical characteristics, treatment practices and patient outcomes, with the objective of establishing a baseline from which SNMM management can be enhanced.
Methods
All newly diagnosed SNMM cases in The Netherlands between 2001 and 2021 were included using data from The Netherlands Cancer Registry (NCR).
Results
A total of 320 patients were included. The annual incidence rate for the overall population was stable over the inclusion period with an annual percentage change (APC) of only − 0.01%. The 5-year overall survival (OS) and relative survival (RS) were 24.5 and 32.4%, respectively. Relative survival did not increase over time. The addition of adjuvant radiotherapy to surgery was not associated with a higher OS and RS compared to surgery alone.
Conclusion
Sinonasal mucosal melanoma is a rare disease with stable incidence rates in the Netherlands between 2001 and 2021. There has been no improvement in survival over the course of the inclusion period. The study reaffirms that adjuvant radiotherapy does not seem to improve patient outcomes. Given the generally poor outcomes for SNMM patients, novel therapeutic options ought to be considered in order to improve care.
Hinweise
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Sinonasal mucosal melanoma (SNMM) is a rare type of cancer that arises from melanocytes in the mucosa of the nasal cavity and paranasal sinuses. The incidence of mucosal melanomas, including SNMM, is much lower than that of their cutaneous counterparts, constituting approximately 1% of all melanoma cases [1]. In the head and neck region, between 60 and 70% of mucosal melanomas originate in the nasal cavity and paranasal sinuses [2, 3]. Of these, the vast majority are situated in the nasal cavity, followed by the maxillary and ethmoid sinuses [4]. The pathogenesis of SNMM is still poorly understood, and no apparent risk factors have been identified to date. Moreover, these tumors are characterized by a distinct molecular profile and mutational signature that differs from cutaneous melanoma [5‐8].
SNMM is characterized by high recurrence rates and poor survival [9‐12]. Surgery is the primary treatment modality for SNMM, aiming to achieve clear surgical margins [4, 13‐16]. This may be difficult to accomplish due to the complex anatomy of the nasal cavity and paranasal sinuses and the close relation to vital structures such as the orbit and the anterior skull base. Additionally, the occurrence of multifocal lesions in up to 25% of patients, possibly linked to extensive field cancerization, further complicates local tumor control [17]. Both open and endoscopic endonasal approaches (or a combination of both) are viable, depending on the extent of disease. However, an endoscopic approach is favored whenever feasible [14, 18]. Radiotherapy, administered following surgery, has been shown to improve local control but does not seem to improve survival [10, 13, 19, 20]. More recently, targeted therapy (e.g. BRAF-inhibitors) and immunotherapy (e.g. anti CTLA-4 and anti-PD-1 antibodies) have greatly influenced the management of (metastatic) cutaneous melanoma. Unfortunately, these treatments have not benefitted patients with mucosal melanoma to the same extent [21, 22]. SNMM survival hence remains unsatisfactory, necessitating the exploration of alternative approaches to manage relapse. The recently published UK guidelines for the management of head and neck mucosal melanoma recommend that rigorous follow-up, consisting of comprehensive clinical assessment and imaging during the first year after treatment could prove helpful in this matter, allowing for timely intervention in case of recurrence [23]. Following the first year, the frequency of follow-up may be gradually reduced. Although this approach has not yet been studied, the underlying reasoning warrants further exploration.
Anzeige
Due to the rarity of SNMM, most evidence regarding treatment selection is based on retrospective studies. Prospective research is difficult to conduct, adding to the importance of (inter)national databases for providing further insight. The present study aims to investigate the trends in the incidence of SNMM in the Netherlands and to identify which patient characteristics and treatment practices impact patient outcomes by using nationwide, prospective data. This research will point out factors associated with outcomes and areas for improvement, as well as successes in current treatment strategies.
Methods
Study population
Data was obtained through a structured query in The Netherlands Cancer Registry (NCR). The NCR is a nationwide database that has captured data on over 95% of newly diagnosed cancer patients in the Netherlands since 1989 [24, 25]. Dedicated registrars compile the registry by gathering data from patient health records based on a minimum dataset, which has expanded over time. All adult patients with a histopathologically confirmed SNMM diagnosed between January 1, 2001 and December 31, 2021 were included. Cases were excluded if an SNMM was discovered during autopsy, but the patient died due to other causes. Morphology and topography codes according to the International Classification of Diseases for Oncology (ICD-O-3) were used to identify cases in the NCR [26]. The topography codes encompassed the nasal cavity (C30.0), maxillary sinus (C31.0), ethmoid sinus (C31.1), frontal sinus (C31.2), sphenoid sinus (C31.3), paranasal sinus overlapping (C31.8), and paranasal sinus not otherwise specified (C31.9). The morphology codes covered malignant melanoma and its morphological subtypes (8720–8722, 8730, 8743, 8745, 8746, 8770–8772) [27].
Operationalization
Tumors were staged according to the 7th edition (between 2010 and 2016) or the 8th edition (2017 onwards) of the Union for International Cancer Control (UICC) TNM-classification for mucosal melanoma of the upper aerodigestive tract [28, 29]. This classification was first introduced as part of the 7th edition. As a result, TNM-classification data was unavailable for patients diagnosed between 2001 and 2009. Information regarding the extent of disease was used to distinguish between local disease (T3-4bN0M0), regional disease (T3-4bN1M0), and distant metastases (T3-4bN0-1M1). The following variables were not available from the onset of the inclusion period because of the continuous expansion of the NCR: disease recurrence and progression were registered from 2017 onward; data regarding surgical margins were registered from 2018 onward. Information on radiotherapy of the neck was not available.
Statistical analysis
The incidence was standardized to the Revised European Standard population and reported as the Revised European Standardized Rate (RESR) expressed per 100,000 [30]. As a result, these rates are comparable over the years despite changes in the size and age composition of the Dutch population. Joinpoint Trend Analysis Software version 4.2.0.2 was used to calculate trends in the standardized incidence rates and reported as an annual percentage change (APC) with 95% confidence intervals (95% CI). Stata/SE version 17.0 was used for all other analyses. Q-Q plots were used to assess normality of data. Patient characteristics were reported as means and standard deviations (SD) or medians with the 25th and 75th percentile (p25-p75) for normally and non-normally distributed variables, respectively. Overall survival (OS) was measured from the date of diagnosis until linkage to the municipal registry to obtain vital status and was calculated using the Kaplan–Meier estimator. The Cox proportional hazards model was used for univariable and multivariable analyses. The proportional hazards assumption was visually tested for categorical variables, and interaction with time was tested for continuous variables. The assumption was met for all variables. The relative survival (RS) rate was defined as the ratio of observed survival in the study population to the expected survival rate in the general Dutch population (obtained from Statistics Netherlands) by age, sex, and year. The relative excess risk (RER) was calculated in a univariable and multivariable model. Age at the time of diagnosis and sex were included in the multivariable analysis regardless of statistical significance. Other variables with a probability (P) value < 0.10 in the univariable analysis were introduced in the multivariable analysis and eliminated in a stepwise-backward fashion. Probability values < 0.05 were considered statistically significant for all tests. The variables multifocality of disease and resection margins were excluded from the analysis due to insufficient data. Calculating disease-free survival was not possible due to the lack of registration of recurrences prior to 2017. In order to ensure an adequate sample size per variable category, “surgery + radiotherapy” and “surgery + systemic (+ radiotherapy)” were grouped for the OS Cox proportional hazard analysis and RER analysis.
Anzeige
Results
Trends in incidence
The RESR and absolute incidence over time in The Netherlands between 2001 and 2021 are displayed in Fig. 1. The number of yearly diagnosed cases ranged from seven in 2004 and 2010 to 29 in 2014. The annual incidence rate for the entire population was stable with an APC of − 0.01% (95% CI − 2.50 to 2.60%. There appeared to be a slight downward trend for male patients (APC = − 1.54%, 95% CI − 4.70 to 1.70%) and a slight upward trend for female patients (APC = 1.57%, 95% CI − 2.30 to 5.60%), but neither was statistically significant.
Fig. 1
Incidence rates of sinonasal mucosal melanoma in the Netherlands between 2001 and 2021. The solid lines represent the annual incidence expressed as RESR. The dashed lines indicate the absolute incidence. RESR revised European standardized incidence rate, APC annual percentage change
×
Study population
The studied cohort consisted of 320 patients with a primary mucosal melanoma of the nasal cavity and paranasal sinuses, diagnosed in the Netherlands between 2001 and 2021. The clinical characteristics are shown in Table 1.
Table 1
Patient characteristics for patients (n = 320) with sinonasal mucosal melanoma diagnosed between 2001 and 2021 in The Netherlands
Age at diagnosis
Median
p25-p75
Years
73
65–81.5
Sex
N
%
Male
146
45.6
Female
174
54.4
Primary tumor site
N
%
Nasal cavity
262
81.9
Maxillary sinus
32
10.0
Ethmoid sinus
14
4.4
Sphenoid sinus
3
0.9
Frontal sinus
2
0.6
Sinonasal NOS
7
2.2
cT classificationa
N
%
T3
95
48.7
T4a
54
27.7
T4b
26
13.3
Unknown
20
10.3
cN classification
N
%
N0
248
77.5
N1
30
9.4
Unknown
42
13.1
cM classification
N
%
M0
287
89.7
M1
33
10.3
Clinical stage (simplified)
N
%
Local disease
237
74.1
Regional disease
24
7.5
Distant metastases
33
10.3
Unknown
26
8.1
Primary tumor treatment modality
N
%
Surgery
63
19.7
Surgery + radiotherapy
176
55.0
Surgery + systemic (+ radiotherapy)b
6
1.9
Radiotherapy
32
10.0
Systemic (+ radiotherapy)c
9
2.8
None/BSC
34
10.6
Follow-up
Median
p25-p75
Median duration (months)
20.2
8.3–43.5
Outcome
N
%
Alive
70
21.9
Deceased
250
78.1
p25-p75 25th and 75th percentile; NOS not otherwise specified
aOnly pertains to cases diagnosed between 2010 and 2021
bIncludes patients treated with surgery followed by either (radiotherapy with subsequent) chemotherapy or immune(radio)therapy
cIncludes patients treated with either (radiotherapy with subsequent) chemotherapy/targeted therapy, or immune(radio)therapy
Out of 320 patients, a slight majority (54.5%) was female. The vast majority of patients (81.9%) presented with a tumor of the nasal cavity. Two hundred thirty-seven patients (74.1%) were diagnosed with local disease, 24 (7.5%) had cervical lymph node metastases, and 33 (10.3%) had distant metastases upon diagnosis. For 26 patients (8.1%), the clinical stage was unknown. A total of 245 patients (76.6%) underwent surgery, with or without adjuvant treatment, 32 (10.0%) received radiotherapy only, and 34 (10.6%) received best supportive care.
Outcome
The median duration of follow-up was 20.2 months (p25-p75, 8.3–43.5). At the time of linkage to the municipal registry, 70 patients (21.9%) were alive and 250 (78.1%) had died. The 1-, 2-, 3-, and 5-year OS for the entire study population were 67.7% (95% CI 62.2–72.6%), 49.0% (95% CI 43.2–54.5%), 34.6% (95% CI, 29.2–40.1%), and 24.5% (95% CI 19.6–29.7%), respectively. The Kaplan–Meier survival estimates for OS, stratified by primary tumor site, clinical stage (simplified), and treatment modality, are shown in Fig. 2.
Fig. 2
Kaplan–Meier survival estimates for overall survival in sinonasal mucosal melanoma in the Netherlands between 2001 and 2021. A is primary tumor site, B is clinical stage (simplified); C is treatment modality. BSC best supportive care
×
The findings of the Cox proportional hazard analysis are shown in Table 2. A statistically significant association was observed with age at the time of diagnosis, primary tumor site, clinical stage, and treatment modality in univariable analysis. This association remained significant for the aforementioned variables in multivariable analysis. Notably, there was no difference in the hazard of dying between patients who underwent surgery and adjuvant treatment, and patients who underwent surgery alone after adjustment for age, tumors site and clinical stage (HR = 1.16, 95% CI 0.80–1.68).
Table 2
Univariable and multivariable Cox proportional hazard analysis for overall survival
Univariable
Multivariablea
HR
95% CI
P-value
HR
95% CI
P-value
Age at time of diagnosis (per 10 years)
1.40
1.24–1.57
< 0.001
1.29
1.13–1.47
< 0.001
Sex
0.258
Male
ref
n.a
Female
0.87
0.68–1.11
Primary tumor site
< 0.001
< 0.001
Nasal cavity
ref
n.a
ref
n.a
Maxillary sinus
1.57
1.06–2.34
1.54
0.98–2.42
Ethmoid sinus
1.08
0.53–2.19
1.07
0.48–2.36
Frontal/sphenoid sinus
6.64
2.68–16.5
6.34
2.40–16.7
Clinical stage simplified
< 0.001
0.003
Local disease
ref
n.a
ref
n.a
Regional disease
1.70
1.09–2.66
1.78
1.08–2.91
Distant metastases
2.70
1.82–4.00
2.03
1.25–3.29
Treatment modality
< 0.001
< 0.001
Surgery
ref
n.a
ref
n.a
Surgery + adjuvant therapyb
1.23
0.87–1.74
1.16
0.80–1.68
Radiotherapy
3.07
1.93–4.90
1.76
1.03–3.02
Systemic (+ radiotherapy)c
1.87
0.84–4.18
0.91
0.34–2.44
None/BSC
10.5
6.51–16.8
4.59
2.54–8.31
Statistically significant P-values are depicted in bold
Age was included as a continuous variable per 10 years
HR hazard ratio, 95% CI 95% confidence interval, BSC best supportive care, n.a. not applicable
aVariables with a P-value < 0.10 in univariable analysis were included in multivariable analysis. Sex was subsequently excluded in a stepwise backward manner
bIncludes both patients who received either surgery + radiotherapy or surgery + systemic (+ radiotherapy)
cIncludes patients treated with (radiotherapy with subsequent) chemotherapy, immune(radio)therapy, targeted therapy, or targeted therapy followed by radiotherapy
The 1-, 2-, 3-, and 5-year RS for the entire cohort were 76.1% (95% CI 70.9–80.5%), 59.6% (95% CI 53.6–65.0%), 43.7% (95% CI 37.1–50.1%), and 32.4% (95% CI 25.7–39.3%), respectively. RS was lower for patients with a tumor of the maxillary sinus compared to those with a tumor of the nasal cavity, regardless of the interval. Additional subgroup analyses for RS could not be performed due to low numbers.
The RER was statistically significant for age, primary tumor site, clinical disease stage, and treatment modality in the univariable analysis (Table 3). This association persisted for all variables except age in a multivariable model. Patients who underwent surgery and adjuvant treatment appeared to have a higher RER (RER = 1.28, 95% CI 0.81–2.02) than patients who underwent surgery alone after adjusting for covariates, although this was not statistically significant (see Fig. 3).
Table 3
Univariable and multivariable relative excess risk (RER) analysis
Univariable
Multivariablea
RER
95% CI
P-value
RER
95% CI
P-value
Age at time of diagnosis (per 10 years)
1.29
1.13–1.48
< 0.001
Sex
0.319
Male
ref
Female
0.86
0.64–1.16
Primary tumor site
< 0.001
0.018
Nasal cavity
ref
ref
Maxillary sinus
1.92
1.25–2.95
1.60
0.97–2.65
Ethmoid sinus
1.29
0.60–2.78
1.12
0.47–2.66
Frontal/sphenoid sinus
9.89
4.03–24.3
3.83
1.44–10.1
Clinical stage simplified
< 0.001
0.005
Local disease
ref
ref
Regional disease
1.80
1.09–2.98
1.57
0.88–2.82
Distant metastases
3.57
2.35–5.43
2.46
1.40–4.32
Treatment modality
< 0.001
< 0.001
Surgery
ref
ref
Surgery + adjuvant therapyb
1.44
0.92–2.26
1.28
0.81–2.02
Radiotherapy
3.81
2.15–6.74
2.04
1.04–4.02
Other
2.64
1.08–6.42
0.73
0.22–2.43
None/BSC
14.3
8.38–24.5
6.95
3.56–13.6
Statistically significant P-values are depicted in bold
Age was included as a continuous variable per 10 years
RER relative excess risk, 95% CI 95% confidence interval, BSC best supportive care
aVariables with a P-value < 0.10 in univariable analysis were included in multivariable analysis. Age at time of diagnosis and sex were subsequently excluded in a stepwise backward manner
bIncludes both patients who received either surgery + radiotherapy or surgery + systemic therapy (+ radiotherapy)
Fig. 3
Relative survival rates at 1, 2, 3, and 5 years for sinonasal mucosal melanoma in the Netherlands between 2001 and 2021, stratified by period of diagnosis, sex, age at time of diagnosis, and tumor site. *3-year and 5-year RS rate for ethmoid sinus patients could not be calculated due to low numbers
×
Discussion
This study underlines the rarity of SNMM in the Netherlands. The incidence rate was stable over the inclusion period. Long-term OS and RS for patients is generally poor and has not significantly improved over time. Moreover, the addition of adjuvant treatment modalities to surgery did not seem to improve outcomes for patients compared to surgery alone.
Anzeige
The APC over standardized incidence rates showed no change over the inclusion period. Previous studies have contrastingly reported increased rates over time. Jangard et al. have reported an upward trend in in Sweden between 1960 and 2000 [31]. A similar upward trend has been reported across Europe and the United States between 2000 and 2007[32]. Because our understanding of the etiology of SNMM is limited, it is unclear what this difference may be attributed to.
Survival rates for patients in this study were poor, with a 5-year OS of 24.5%, which is in line with previous literature: reported 5-year OS rates varied between 22 and 28% [10‐12, 33]. This poor survival of patients is reflected in the UICC TNM-classification for mucosal melanoma of the upper respiratory tract in which T-stage starts at T3. However, this staging system has been shown to insufficiently correlate with prognosis [34, 35]. Clinically manifested lymph node metastases were found in 9.4% of patients, slightly exceeding the proportion of clinical regional disease (7–8%) reported by previous studies [11, 31, 33]. Information on (elective) treatment of the neck was not available for this cohort. Elective neck treatment is not commonplace because of the infrequent occurrence of occult nodal metastases in cN0 SNMM patients [11, 23]. Sentinel lymph node biopsy has been widely adopted and incorporated into standard care for cutaneous melanoma. However, there is limited evidence supporting this procedure in SNMM [36, 37]. The majority of patients in this cohort were treated with surgery and adjuvant radiotherapy. Notably, these patients had worse OS and RS compared to those who underwent surgery alone. Although adjuvant radiotherapy has been shown to improve local control, it does not appear to influence OS [8, 10, 19, 38, 39]. Outcomes for those who received radiotherapy alone were significantly worse. This was most likely due to bias by indication, given that single modality radiotherapy is typically reserved for palliative patients or those unfit for surgery. Primary radiotherapy appears to have little effect on outcomes [33, 39, 40].
Only eight patients had been treated with systemic therapy, being either targeted therapy (i.e. BRAF-inhibitors) or immunotherapy (ipilimumab, nivolumab, or pembrolizumab). As such, the influence of these treatment modalities on survival could not be adequately assessed. Targeted therapy has shown excellent results in metastasized cutaneous melanoma as BRAF-mutations are present in more than half of all patients [41]. In contrast, BRAF-mutations have been described in less than 10% of SNMM cases [8, 42‐44]. Although the introduction of immunotherapy has greatly influenced care for patients with cutaneous melanoma, there has not been a similar improvement in survival for SNMM patients [21, 22]. There is a clear need for identification of new therapeutic targets and beneficial management strategies for SNMM. The role of immunotherapy, in the adjuvant setting, either with or without radiotherapy as well as the efficacy of several novel compounds, are currently under investigation [45] .
The present study cohort was assembled using the NCR where trained data registrars, ensuring meticulous data accuracy, collect data from the patient’s health record 5–9 months after diagnosis. It is imperative, however, to acknowledge several limitations. The extraction of information by registrars was contingent upon its recording in a patient's health record, thereby underscoring the significance of consistent and detailed documentation practices across individual hospitals. Information regarding treatment intent was not available and as such the distinction between curative and palliative treatment could not be made. Furthermore, cause of deaths was not available so cancer-specific death could not be analyzed. However, relative survival provided a close approximation of disease-specific survival. Similarly, data on disease progression or recurrence would have been helpful to be able to better understand the path from diagnosis to death. Unfortunately, this information was not available in sufficient detail at the time of this study. However, future reports are expected to be able to provide further insight as the collection of these variables has started in 2017.
Anzeige
Conclusion
Sinonasal mucosal melanoma is a rare disease with stable incidence rates in The Netherlands between 2001 and 2021. There has been no improvement in survival over the course of the inclusion period. Moreover, adjuvant radiotherapy does not seem to improve patient outcomes. Given the generally poor outcomes for SNMM patients, novel therapeutic strategies ought to be considered in order to improve care.
Acknowledgements
The authors would like to acknowledge the registration team of the Netherlands Comprehensive Cancer Organization (IKNL) for their data collection efforts for the Netherlands Cancer Registry.
Declarations
Conflict of interest
The authors declare no conflicts of interest.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med HNO erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes HNO, den Premium-Inhalten der HNO-Fachzeitschriften, inklusive einer gedruckten HNO-Zeitschrift Ihrer Wahl.
Sinonasal mucosal melanoma in The Netherlands between 2001 and 2021: a clinical and epidemiological overview of 320 cases
verfasst von
W. F. Julius Scheurleer Lise J. van de Velde Lot A. Devriese Mischa de Ridder Marieke W. J. Louwman Gerben E. Breimer Remco de Bree Boukje A. C. van Dijk Johannes A. Rijken
Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.
Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.
Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.
Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.
Update HNO
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.
